ENLV - CIK 0001596812
The table below shows Enlivex Therapeutics Ltd.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $3.75M | $3.46M | $20.15M | $12.61M | $10.16M |
| Short-term investments | $6.00K | $228.00K | $25.44M | $62.92M | $67.96M | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.32M |
| $28.57M |
| $30.79M |
| $65.05M |
| $92.83M |
| $34.33M |
| Property, plant & equipment | $490.00K | $1.16M | $9.57M | $6.52M | $1.69M | $696.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $22.60M | $31.90M | $53.03M | $77.34M | $95.19M | $35.44M |
| Accounts payable | - | $303.00K | - | - | - | - |
| Total current liabilities | $3.33M | $2.84M | $4.99M | $4.21M | $4.58M | $5.01M |
| Long-term debt | - | - | $7.16M | - | - | - |
| Total liabilities | $3.54M | $3.34M | $8.69M | $8.86M | $4.98M | $5.25M |
| Retained earnings | -$132.43M | -$119.33M | -$97.03M | -$70.10M | -$43.80M | -$29.51M |
| Total equity | $19.05M | $28.56M | $44.34M | $68.49M | $90.21M | $30.19M |